CORAL LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 76 | 78 | 84 | 115 | 86 |
| EBITDA (ex other income) | 9 | 4 | 16 | 25 | 16 |
| margin % | 12.1 | 4.9 | 19.2 | 22.1 | 18.1 |
| Owners' profit | 9 | 6 | 16 | 24 | 16 |
| EPS, as reported (₹) | 25.32 | 18.04 | 44.19 | 67.61 | 45.85 |
| ROE % · ROCE % | 5.8 · 7.3 | 4.2 · 5.3 | 8.9 · 11.5 | 12.0 · 15.9 | 7.8 · 10.9 |
| Debt / equity (x) | 0.04 | 0.00 | 0.00 | 0.02 | 0.02 |
| Cash from operations | 6 | 13 | (5) | (1) | 16 |
| Capex | (6) | (2) | (1) | (3) | (21) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 32 | 23 | 28 | 19 | 19 | 22 | 26 |
| Profit before tax | 12 | 9 | 8 | 4 | 4 | 7 | 4 | 8 |
| Net profit | 9 | 6 | 6 | 3 | 3 | 6 | 3 | 5 |
| EPS (₹) | 24.64 | 17.86 | 17.20 | 7.91 | 7.18 | 16.29 | 7.77 | 14.62 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Newspaper ad on 44th AGM notice, annual report dispatch and e-voting details | compliance | minimal | — | — |
| 4 Sept 2026 · 44th AGM notice and FY2025-26 annual report with Rs 2 dividend proposed | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · Coral Laboratories 44th AGM on September 29, 2026 via video conferencing | board shareholder meetings | medium | — | — |
| 3 Sept 2026 · Newspaper publication of 44th AGM notice, book closure and dividend | compliance | minimal | — | — |
| 6 Aug 2026 · Newspaper notice on transfer of unclaimed shares to IEPF | compliance | minimal | — | — |
| 5 Aug 2026 · Board meeting on Aug 14 to consider Q1 FY27 results and 44th AGM | results | low | — | — |
| 23 Jul 2026 · Postal ballot result: remuneration hike for Meera Doshi approved | management changes | medium | — | — |
| 23 Jul 2026 · Postal ballot approves higher pay for related party Ms. Meera Doshi | management changes | medium | — | — |
| 14 Jul 2026 · Quarterly RTA certificate for share dematerialization | compliance | minimal | — | — |
| 25 Jun 2026 · Coral Labs says price movement is purely market driven | regulatory legal | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.8 | 28.9 | 33 of 169 | 81% |
| P/B | 1.0 | 3.3 | 20 of 163 | 88% |
| ROCE | 10.8 | 10.8 | 90 of 183 | 51% |
| ROE | 7.8 | 10.4 | 101 of 171 | 41% |
| Debt / Equity | 0.0 | 0.1 | 57 of 171 | 67% |
| EBITDA margin | 33.4 | 17.5 | 23 of 165 | 87% |
| Revenue growth | (5.9) | 16.3 | 130 of 161 | 19% |
| Profit growth | 84.8 | 30.9 | 40 of 158 | 75% |
| Market cap | 209 | 839 | 114 of 182 | 38% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
